Recurrent Breast Cancer Completed Phase 2 Trials for Foretinib (DB12307)

Also known as: Breast Cancer Recurrent / Breast cancer NOS recurrent / Carcinoma breast recurrent / Breast carcinoma recurrent / Breast carcinoma NOS recurrent

IndicationStatusPhase
DBCOND0028640 (Recurrent Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01147484A Study of Foretinib in Patients With Recurrent/Metastatic Breast CancerTreatment